Treatment for Acute Mania: Safety, Medication, and Specialist Care
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Treatment for acute mania begins with a prompt assessment of safety, medical causes, and the severity of the mood episode. Depending on the presentation, a specialist may recommend urgent psychiatric evaluation, hospital care, an antimanic medication such as an antipsychotic or lithium, or a carefully selected combination. The immediate goals are to reduce manic symptoms, restore sleep and judgment, prevent physical and financial harm, and begin planning for recovery. The precise sequence depends on clinical findings, treatment history, patient preferences, and local availability. NICE CG185 VA/DoD 2023
Acute mania is treatable, but severe episodes can escalate quickly. A person who is unable to sleep for days, is dangerously impulsive, has delusions or hallucinations, cannot meet basic needs, or poses an immediate danger needs urgent in-person care. In the United States, call 911 for an immediate threat or go to the nearest emergency department. For suicidal thoughts or an emotional crisis, call or text 988; 988 does not replace emergency medical services when immediate physical safety is at risk. NIMH VA/DoD
What is acute mania, and why does treatment differ from other bipolar phases?
A manic episode is a distinct period of abnormally elevated, expansive, or irritable mood with markedly increased energy or activity and associated changes such as a decreased need for sleep, unusually rapid speech, racing thoughts, grandiosity, distractibility, and potentially dangerous decisions. Under DSM-5-TR diagnostic framing, a full episode generally lasts at least one week, or any duration if hospitalization is necessary, and causes marked impairment or includes psychotic features. Treatment begins when clinicians identify a potentially dangerous syndrome; care should not wait for the calendar threshold to pass. VA/DoD clinical guideline
Mania differs from hypomania in the degree of impairment and the possible need for hospitalization, and psychosis makes an episode manic rather than hypomanic. Bipolar I disorder is characterized by at least one manic episode, while bipolar II disorder involves hypomanic and major depressive episodes without a history of full mania. A newly observed manic syndrome may also be related to a drug, a substance, or another medical condition, so the clinical assessment must establish the likely cause rather than assuming every manic presentation is bipolar I disorder. NIMH bipolar disorder VA/DoD
Medication evidence is phase-specific. Trials that establish an agent's effectiveness for acute bipolar depression or prevention of future episodes do not establish its ability to stop a current manic episode. A medication can be useful later in the illness and still have little direct benefit for acute mania. For an overview of the broader treatment plan, see Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care; this article concentrates on the acute manic phase. CANMAT/ISBD update For phase-specific detail, see Bipolar Depression Treatment: Medications, Therapy, and Evidence.
When does acute mania require emergency or hospital care?
Urgency is determined by current risk and capacity to function, not simply by how energetic, cheerful, or talkative someone appears. Warning signs include extreme sleep loss, reckless driving or spending, violent or threatening behavior, psychotic beliefs, severe agitation, rapidly worsening confusion, refusal of necessary food or fluid, suicidal ideas, and an inability to use judgment safely. Mania with severe depression-like symptoms or agitation also deserves careful suicide-risk assessment. A related symptom guide explains when manic symptoms require urgent help. NICE CG185 VA/DoD
Hospitalization is considered when intensive observation, rapid assessment, supervised medication, or protection from immediate harm cannot be provided safely in the community. Inpatient care allows clinicians to monitor sleep, nutrition, hydration, physical health, adverse medication effects, psychosis, and fluctuations in judgment. Other people may be treated through a crisis team, an intensive outpatient service, or urgent specialist follow-up when safety can be maintained reliably. The least restrictive safe setting is chosen through an individualized clinical assessment. NICE CG185 VA/DoD
What should happen during a crisis?
If you are with someone whose behavior suggests severe mania, prioritize calm surroundings and access to urgent assessment. Speak in short, respectful sentences; avoid arguing about grandiose or paranoid ideas; reduce unnecessary noise and stimulation; and give healthcare professionals concrete observations about sleep, medication changes, substances, threats, and functional decline. Arrange transportation through an appropriate medical or crisis service when driving or judgment is unsafe. Never physically restrain someone, administer another person's medication, or try to manage serious aggression without trained help. NICE CG185 NICE NG10
When a person declines care, clinicians assess their decision-making capacity for the particular decision and the immediacy of safety concerns. Capacity may vary within an episode and is evaluated, not presumed absent because a person has a diagnosis. Emergency evaluation and involuntary treatment are governed by jurisdiction-specific laws, clinical criteria, and procedural protections. A well-established advance directive or psychiatric crisis plan can help communicate earlier preferences when the person is temporarily unable to do so. VA/DoD
The first clinical assessment: safety, diagnosis, and medical stability
The initial evaluation should document the onset and duration of symptoms, mood and energy changes, sleep, activity, psychotic symptoms, current medications, adherence, recent antidepressant or stimulant exposure, alcohol and other drug use, previous episodes, treatment responses, and family observations when appropriate. Clinicians assess suicide and violence risk, ability to care for oneself, current physical illness, and the availability of reliable support. The purpose is to identify the immediate treatment setting and the most plausible underlying syndrome. VA/DoD clinical guideline
A new manic presentation can overlap with intoxication, withdrawal, delirium, neurological disease, endocrine abnormalities, medication reactions, and other psychiatric conditions. An especially abrupt change in an older adult, fluctuating attention or consciousness, fever, seizures, or significant autonomic abnormalities raises concern for a medical process. The examination, targeted laboratory work, pregnancy assessment when relevant, and further tests depend on the history and clinical findings; there is no blood test that independently diagnoses bipolar disorder. VA/DoD NIMH
Before and during antimanic pharmacotherapy, the clinician considers vital signs, hydration, kidney and liver function, blood count, glucose and lipids, pregnancy potential, drug interactions, and cardiac risk as appropriate for the selected agent. When lithium is contemplated, kidney and thyroid assessment and a plan for blood-level monitoring are particularly important. These tests serve medication safety and medical differential diagnosis; their necessity and timing vary by setting and the patient's acute condition. NICE CG185 VA/DoD
How is acute mania treated with medication?
The strongest established medication options for adult acute bipolar mania include several antipsychotics, lithium, and valproate-containing medicines, with selection guided by the person's previous response, illness severity, coexisting conditions, reproductive considerations, and monitoring feasibility. Medication can be started or adjusted promptly by a qualified prescriber, especially when major impairment or safety risks are present. A randomized-trial network meta-analysis and the major clinical guidelines support the efficacy of multiple established antimanic agents, although comparative rankings and certainty differ. Huang et al. 2025 CANMAT/ISBD
There is no universal prescription that fits every episode. The 2023 U.S. VA/DoD guideline suggests lithium or quetiapine as monotherapy, then offers olanzapine, paliperidone, or risperidone among alternatives depending on preferences and clinical characteristics. NICE places several antipsychotics at the beginning of its acute-mania pathway, including haloperidol, olanzapine, quetiapine, and risperidone. CANMAT/ISBD lists additional evidence-supported agents, including asenapine, aripiprazole, and cariprazine. Differences reflect evidence interpretation, clinical context, licensing, and prescribing systems rather than a contradiction about whether mania needs treatment. VA/DoD NICE CG185 CANMAT/ISBD
Antipsychotics: frequently used for initial symptom control
Antipsychotic medications can reduce manic excitement, disorganized or racing thoughts, severe irritability, and psychotic symptoms. Clinically used options include quetiapine, olanzapine, risperidone, aripiprazole, asenapine, cariprazine, and haloperidol, among others; individual approvals and formulations vary. Some have useful sedating properties when insomnia and agitation are prominent, whereas others are less sedating. Selection is based on the overall risk-benefit profile, not on sedation alone. VA/DoD CANMAT/ISBD
Adverse effects vary substantially across agents and include sleepiness, dizziness, restlessness or akathisia, stiffness or other movement symptoms, weight gain, changes in blood sugar or lipids, orthostatic hypotension, and, with certain drugs or risk profiles, heart-rhythm effects. Older first-generation agents such as haloperidol may be associated with more extrapyramidal symptoms; some second-generation agents carry a greater metabolic burden. An antipsychotic prescription therefore requires both near-term tolerability checks and a plan for metabolic and movement-symptom monitoring. NICE CG185 VA/DoD
Psychotic symptoms may make treatment more urgent, but not all mania includes hallucinations or delusions. Antipsychotic choice takes account of whether the person has psychosis, agitation, poor oral intake, a previous adverse reaction, or a history of not taking medication regularly. The immediate objective is stabilization and safety, followed by regular review of whether the agent and formulation remain appropriate. Read more about psychotic symptoms in bipolar disorder. NICE CG185
Lithium: effective antimanic treatment with essential monitoring
Lithium is an evidence-based antimanic medication that can also be important in long-term bipolar management. It may be particularly attractive when a person previously benefited from lithium and when ongoing monitoring is feasible. Its pharmacological benefits must be balanced against a narrow therapeutic index: blood concentrations that are too high can cause serious toxicity. Lithium is prescribed and adjusted using kidney function, clinical condition, drug interactions, and standardized blood-level testing, rather than symptom impressions alone. VA/DoD DailyMed lithium label
Dehydration, sodium depletion, kidney impairment, and certain interacting drugs can increase lithium concentrations. Commonly implicated interacting medicines include nonsteroidal anti-inflammatory drugs, some diuretics, and agents that affect kidney blood flow. Symptoms concerning for toxicity include significant tremor, vomiting or diarrhea, marked weakness, unsteady walking, confusion, or pronounced drowsiness. These require prompt medical assessment; severe neurological symptoms constitute an emergency. The clinician monitors kidney and thyroid function and discusses fluid intake and illness-related precautions. DailyMed lithium label NIMH medications
Blood testing is particularly important after lithium initiation, dose adjustments, interacting medication changes, and during intercurrent illness. A single concentration should be interpreted relative to the time since the last dose and the person's clinical status. Never use an internet dose chart to start lithium or change it independently; a clinician must establish the schedule and monitoring plan. DailyMed lithium label
Valproate or divalproex: an alternative with major reproductive and organ-safety concerns
Valproate products, including divalproex, have evidence for acute mania and may be considered in selected patients. They are not interchangeable with other mood stabilizers in benefits and harms. Clinicians review liver health, blood counts and platelets, pancreatitis history, concomitant drugs, and the likelihood of pregnancy before prescribing. Liver injury, pancreatitis, thrombocytopenia, and clinically important drug interactions are established concerns. Monitoring follows the product labeling and the individual's clinical circumstances. VA/DoD DailyMed divalproex
Valproate carries serious fetal risks, including congenital malformations and adverse neurodevelopmental outcomes after exposure during pregnancy. People who are pregnant, planning pregnancy, or may become pregnant require particularly careful specialist consultation about safer alternatives, contraception where appropriate, and a documented individualized plan. Some national regulators impose additional restrictions; local rules and product labeling govern prescribing. Clinicians should also discuss reproductive risks with patients who produce sperm when applicable, using current jurisdiction-specific guidance. An existing prescription should not be stopped abruptly without professional advice, because stopping antimanic therapy can also cause harm. DailyMed divalproex label NICE CG185
When clinicians combine medicines
In more severe mania, with a partial response, or when an episode breaks through an established regimen, clinicians may combine an antipsychotic with lithium or valproate. The VA/DoD guideline specifically suggests several such combinations after unsatisfactory response or breakthrough mania on monotherapy. A 2025 systematic review of 113 randomized studies involving 23,491 adults found that antipsychotic-plus-lithium-or-valproate combinations were generally more effective than the corresponding single agents in the included short-term trials. Greater efficacy must be weighed against additive adverse effects and monitoring demands. VA/DoD Huang et al.
A combination is not synonymous with adding drugs indefinitely. The clinical team checks whether the current dose and duration were adequate, whether the medication was taken consistently, whether substances or sleep disruption are contributing, and whether a safer alternative is possible. Unnecessary simultaneous use of two antipsychotics is generally discouraged, and medicines that did not help should be reviewed rather than automatically accumulated. The best combination depends on the full clinical context and cannot be inferred from an online ranking. VA/DoD
What medicines are not established treatments for a current manic episode?
Lamotrigine
Lamotrigine has a role in aspects of long-term bipolar management and depressive-predominant illness, but it is not an established acute antimanic treatment. NICE explicitly advises against offering it to treat mania, and the VA/DoD guideline suggests against lamotrigine monotherapy for acute mania. Its slow titration is partly dictated by the risk of severe rash, including Stevens–Johnson syndrome and toxic epidermal necrolysis. Valproate changes lamotrigine metabolism and the dosing and rash-risk considerations, making unsupervised adjustments especially dangerous. NICE CG185 VA/DoD DailyMed lamotrigine label
Antidepressants
Antidepressants do not treat an acute manic episode and, in some people with bipolar disorder, may contribute to mood switching or destabilization. NICE advises considering stopping an antidepressant when mania or hypomania develops and reviewing it with the prescriber. The response depends on the particular drug, co-prescribed treatments, and risks of discontinuation; patients should not abruptly stop or change antidepressants without medical supervision. Acute bipolar depression has a different treatment evidence base and belongs in a separate clinical pathway. NICE CG185 NIMH
Sedatives, stimulants, and treatments with insufficient evidence
Short-term sedating medication may be used by trained clinicians for severe insomnia or agitation during a crisis, but sedation is not the same outcome as sustained control of mania. Benzodiazepines may be used as adjuncts in selected monitored settings, while their risks include excessive sedation, respiratory effects when combined with other depressants, falls, and dependence. The VA/DoD guideline reports insufficient evidence to recommend benzodiazepines alone as an evidence-based antimanic regimen. It also suggests against topiramate or brexpiprazole monotherapy for acute mania. VA/DoD NICE NG10
Stimulants, corticosteroids, antidepressants, and recreational substances can sometimes complicate the clinical picture or worsen elevated mood. Whether an existing medication contributes is a diagnostic question for the treating clinician; independently stopping treatment may create withdrawal problems or destabilize another illness. An assessment should review both prescribed and nonprescribed substances rather than assuming that a drug exposure fully explains every symptom. VA/DoD
Acute agitation: rapid calming measures versus longer-term antimanic treatment
If a person is severely agitated, the first clinical response is often verbal de-escalation and a low-stimulation setting, with attention to medical precipitants and individual communication needs. When the immediate risk cannot be controlled with these measures, clinicians may consider rapid tranquilization according to local emergency protocols. This approach is a time-limited safety measure; it does not replace the diagnosis and ongoing treatment of a manic episode. Restraint and other restrictive interventions require strict clinical and legal safeguards and continuous review. NICE NG10
Before administering an emergency sedative or antipsychotic, staff consider intoxication, respiratory disease, other sedating agents, cardiac risk, and previous medication reactions. After treatment, observation includes consciousness, breathing, circulation, and other relevant clinical measures. Oral administration is considered when feasible and accepted; an injectable intervention may be considered when immediate circumstances require it. These decisions belong to trained services with the equipment and staff to manage complications. NICE NG10
What if first-line treatment does not work?
A less-than-expected response should trigger structured reassessment rather than a conclusion that the illness is untreatable. Clinicians review the diagnosis, adherence, substance exposure, medical illnesses, sleep loss, side effects limiting therapeutic use, and whether enough time has passed to judge the medication. They may change the antipsychotic, use or optimize an evidence-supported mood stabilizer, or introduce a carefully selected combination. The preferred next step depends on the previous regimen and the patient's physical and psychiatric risks. VA/DoD NICE CG185
Research comparing acute mania treatments has important limitations. Trials generally last only several weeks and tend to exclude some of the people who are most medically complicated or acutely unsafe. In a 2025 network meta-analysis, the mean trial duration was approximately 3.4 weeks. Prominent ranking of an experimental drug from one or two small studies does not establish routine clinical suitability. Established treatments are chosen using reproducible evidence, regulatory context, guideline strength, and safety monitoring together. Huang et al. 2025
Electroconvulsive therapy for prolonged, severe, or life-threatening mania
Electroconvulsive therapy (ECT) can be considered by specialist teams for prolonged or severe mania when other treatments have failed, are poorly tolerated, or the clinical situation is life-threatening and requires a rapid response. ECT is performed under anesthesia with appropriate medical assessment and monitoring. The decision involves potential benefits, cognitive and other adverse effects, the clinical urgency, patient preferences, and consent procedures. NICE recognizes ECT as an option under such circumstances; it is not routine first-line treatment for uncomplicated mania. NICE CG185 NIMH brain stimulation
How quickly can treatment improve acute mania?
The treatment course is usually evaluated over days and weeks, with closer early monitoring when symptoms are severe. Some agitation and insomnia may improve before grandiosity, disorganization, or impaired judgment resolve. The timing depends on the medicine, severity, adherence, associated psychosis, and medical circumstances; it cannot be predicted from diagnosis alone. Many short-term randomized trials assess outcomes across roughly three to four weeks, while an individual may require a different duration of intensive care and a longer recovery period. Huang et al. 2025 NICE CG185
A falling symptom score does not necessarily mean a person is ready to drive, return to high-risk financial decisions, resume a demanding schedule, or discontinue close follow-up. Clinicians also evaluate sleep regularity, insight, safe behavior, ability to manage medication, family circumstances, and residual depressive symptoms. Recovery of confidence, employment functioning, and relationships may progress more slowly than the acute change in energy or speech. VA/DoD NIMH
Monitoring treatment in hospital and after discharge
Daily clinical monitoring during the episode
During acute treatment, staff repeatedly assess sleep, mood intensity, irritability, psychosis, impulsivity, appetite and hydration, medication adherence, and the ability to function safely. They monitor side effects and medical parameters relevant to the drugs being used. Families or trusted supporters can describe changes from baseline if the patient consents or if limited information sharing is legally justified for immediate safety. These longitudinal observations are more useful than treating one energetic afternoon as proof that mania has ended. VA/DoD NICE CG185
Laboratory and physical-health monitoring
Medication-specific monitoring has a clear purpose: lithium blood concentrations, kidney and thyroid function; relevant liver and hematological measures for valproate; and weight, metabolic status, blood pressure, movement symptoms, and selected cardiac measures for antipsychotics. The cadence depends on acute illness, the prescribed agent, comorbidity, and the stage of treatment. A clinician should provide the actual follow-up schedule in writing, including who reviews results and what new symptoms require prompt contact. NICE CG185 DailyMed lithium DailyMed divalproex
Safety planning at discharge
Leaving an emergency department or inpatient service should involve a practical transition plan. This commonly identifies the responsible prescribing clinician, follow-up appointment, medicine list, monitoring dates, warning signs, crisis contacts, and a way for supporters to raise concerns. Where relevant, the plan addresses safe transportation, return to school or work, accumulated bills, disrupted sleep, and support with decision making. Any return to independent activity should match current functioning rather than a fixed number of days since admission. VA/DoD NICE CG185
Sleep, routine, and psychosocial care during acute mania
Sleep disruption is both a prominent sign of mania and an important target of supportive care. Clinicians often reduce stimulating activities, establish predictable sleep–wake times, address substance use, and limit overwhelming demands while medications take effect. These measures help create conditions for recovery but do not replace evidence-based medication in significant acute mania. After initial stabilization, structured education and work on sleep and daily rhythms can contribute to long-term prevention. See Bipolar Disorder and Sleep for the broader disorder-specific evidence. NICE CG185 NIMH
Psychotherapy can help a person process an episode, strengthen treatment engagement, rebuild relationships, and recognize early warning signs. During florid mania with major loss of judgment, intensive insight-oriented discussion or complex behavioral assignments may be unrealistic. In this stage, clinical teams prioritize simple, collaborative communication, practical support, and crisis stabilization. As the episode subsides, psychoeducation, family-focused approaches, and other structured psychosocial interventions can be integrated into longer-term care. NIMH VA/DoD
The person's preferences remain relevant throughout treatment. Clinicians can offer choices where possible, explain expected benefits and common adverse effects in accessible language, revisit earlier decisions as concentration improves, and record the patient's goals for recovery. A prior crisis plan may specify preferred medications, adverse reactions, trusted contacts, or environmental adjustments. Shared decision-making becomes especially important when planning maintenance treatment after the emergency has passed. VA/DoD
Mania with psychotic symptoms or mixed features
Psychotic features, including fixed delusional beliefs or hallucinations in the setting of mania, increase diagnostic and safety complexity. Some people with mania may become convinced that they have exceptional powers, vast resources, or a unique mission; others develop paranoid ideas. A specialist evaluates whether psychosis occurs exclusively during mood episodes, whether there may be a substance-related or medical cause, and which supervised treatments are indicated. The psychotic presentation may make hospital treatment more appropriate. Read the detailed discussion of psychotic symptoms in bipolar disorder. VA/DoD
A manic episode can also have mixed depressive features, such as hopelessness, guilt, or suicidal thinking occurring alongside high energy, agitation, or reduced need for sleep. NICE advises using the mania treatment pathway for a mixed affective presentation while monitoring closely for depression. These patients require explicit attention to suicide risk, especially when energy and distress coexist. Drug evidence for the heterogeneous mixed-features group is less direct than for typical acute mania, making careful clinical follow-up essential. See Bipolar Disorder With Mixed Features. NICE CG185 VA/DoD
Children, pregnancy, postpartum periods, and older adults
Children and adolescents
Young people need age-appropriate specialist assessment before clinicians label a presentation manic or initiate a long-term regimen. Distinguishing episodic mania from developmental variation, ADHD, trauma-related symptoms, sleep loss, substance effects, and other psychiatric conditions requires history from multiple settings and caregivers as appropriate. Medication safety, side effects, school functioning, family involvement, and age-specific approval status all matter. Adult treatment meta-analyses cannot simply be applied to children. Specialist child and adolescent protocols and local regulatory indications govern choices. NICE CG185 NIMH
Pregnancy and the postpartum period
Acute mania during pregnancy or after childbirth needs coordinated psychiatric and obstetric assessment because both the episode and some medication exposures carry important risks. Postpartum presentations with severe insomnia, confusion, delusions, or sudden behavioral change warrant emergency evaluation, including consideration of postpartum psychosis and medical causes. Valproate has particularly serious reproductive safety concerns, while the suitability of lithium and antipsychotics depends on individualized specialist assessment. Patients who discover a pregnancy while taking medication should promptly contact their clinicians rather than abruptly stopping treatment. NICE CG185 DailyMed divalproex
Older adults and medically complex patients
New manic symptoms late in life require close attention to neurological conditions, delirium, medication effects, endocrine disease, and underlying physical illness. Kidney function, interactions, sensitivity to sedation, fall risk, and metabolic burden can substantially alter treatment choices. In particular, lithium and sedating antipsychotics may require more intensive monitoring. This is an area in which evidence from younger adult acute-mania trials may transfer imperfectly, so specialist medical-psychiatric collaboration has practical value. VA/DoD DailyMed lithium
How can family members and supporters help?
A supporter can make a useful clinical contribution by documenting the date of symptom change, sleep duration, unsafe behaviors, recent medication changes, and unusual beliefs, then sharing those facts with treating professionals through appropriate channels. Nonjudgmental statements work better than prolonged disputes about whether the person is acting 'crazy' or is 'really bipolar.' It is reasonable to ask about consent-based involvement in appointments and a crisis plan, while respecting the person's autonomy and privacy. VA/DoD NIMH
Where judgment is severely impaired, supporters may help postpone costly contracts, major travel, driving, public posts, or other irreversible decisions, using legal and consensual arrangements whenever possible. They can also protect their own safety and avoid taking responsibility for treating a dangerous crisis without assistance. After stabilization, discussing which steps felt helpful and which felt intrusive can improve the next plan. For patterns that may precede another episode, review Early Warning Signs of Mania and Bipolar Relapse. NICE CG185
What happens after acute mania improves?
Once the immediate episode resolves, treatment moves into a longer-term conversation about recurrence prevention, medication tolerability, psychosocial support, and rebuilding everyday functioning. NICE recommends discussing the ongoing treatment choice within four weeks of symptom resolution, including whether to continue the acute treatment or start a different long-term plan. This decision should consider previous manic and depressive episodes, early warning signs, patient preferences, medical monitoring, and the likelihood of future relapse. NICE CG185
A medication that stopped mania may or may not be the best sole maintenance option; conversely, a medicine useful for preventing depression may not have been appropriate for stopping mania. Continuing treatment, adjusting it, or changing medicines all require a planned review. Abrupt self-directed discontinuation, especially after a distressing hospital stay, can be risky. The broader recovery plan links symptom management with sleep regularity, physical health, follow-up, and meaningful activities. NIMH CANMAT/ISBD For phase-specific detail, see Bipolar Maintenance Treatment: Preventing Relapse Over Time.
Common misunderstandings about treatment for mania
A person can have mania without feeling euphoric. Irritability, agitation, hostility, and relentless activity can dominate. Antipsychotic medications can be appropriate even when a patient does not report hallucinations or delusions, because they also have proven antimanic effects. A brief period of calm after a sedative is not the same as recovery from the episode, and the absence of psychosis does not prove that functioning is safe. NIMH VA/DoD
Bipolar II disorder is not merely 'mild bipolar I,' and hypomania is a distinct clinical episode rather than an alternative label for dangerous or psychotic mania. When someone with a prior bipolar II diagnosis develops true mania, the diagnosis warrants reassessment. Ordinary changes in mood or a busy week do not meet diagnostic requirements for a manic episode. An online checklist can prompt assessment but cannot determine the right medication or treatment setting. VA/DoD NIMH
Treatment failure cannot be inferred from one day of continuing symptoms or one unsuccessful prescription. Nor does the best ranking in a network meta-analysis automatically identify the optimal medication for an individual. Guidelines combine efficacy with certainty of evidence, population and indication, clinical urgency, monitoring resources, and adverse-effect profiles. Different agencies can make different first-line choices while drawing on overlapping trial evidence. Huang et al. 2025 VA/DoD
Frequently asked questions about acute mania treatment
What is the first-line treatment for acute mania?
For many adults, an evidence-supported antipsychotic or lithium is a first-line option, with the actual choice depending on severity, medical history, monitoring, and the prescriber's guideline. The VA/DoD guideline suggests lithium or quetiapine monotherapy; NICE commonly starts with selected antipsychotics. Some people need a combination when monotherapy is inadequate. There is no single drug that every person with acute mania should receive. VA/DoD NICE CG185
Can a manic episode go away without medication?
The natural course of mania varies, but untreated severe mania carries risks involving sleep deprivation, judgment, finances, relationships, accidents, and sometimes psychosis or physical health. Waiting for it to resolve without clinical assessment is unsafe when symptoms are significant. Evidence-based treatment can reduce acute symptoms, and urgent care is appropriate when safety or basic functioning is threatened. Mild or diagnostically uncertain presentations still deserve a structured assessment rather than an automatic prescription. NIMH VA/DoD
Is hospitalization always necessary for mania?
No. Hospitalization is considered according to risk, impairment, psychosis, capacity, and whether safe treatment can be delivered elsewhere. Severe or escalating mania often requires supervised care. Some people with less dangerous symptoms and reliable support may receive intensive outpatient management with frequent specialist review. A clinician evaluates the actual risks and resources rather than using a fixed rule based on diagnosis alone. NICE CG185
Does lithium work for acute mania?
Yes. Lithium has randomized-trial evidence and is included in major clinical guidelines for acute mania. It requires baseline assessment, carefully scheduled blood-level monitoring, and attention to kidney and thyroid health, hydration, and drug interactions. A clinician may prefer an antipsychotic or a combination in particular urgent circumstances. Lithium should never be independently started or adjusted on the basis of online advice. VA/DoD DailyMed lithium
What is the fastest way to calm severe agitation in mania?
A trained team first assesses danger, medical contributors, and opportunities for verbal de-escalation. If immediate risk remains high, supervised short-term medication may be used under an emergency protocol, with vital-sign and consciousness monitoring. Calming someone rapidly does not complete the treatment of mania, which also requires an antimanic plan and ongoing assessment. Severe agitation, threats, or a marked loss of judgment warrant urgent in-person evaluation. NICE NG10 VA/DoD
Can antidepressants make mania worse?
In susceptible individuals, antidepressants can contribute to switching into mania or to mood destabilization. When mania occurs, clinicians review the antidepressant and may recommend changing or discontinuing it as part of a supervised treatment plan. The safety of any medication change depends on the drug, prior use, co-treatment, and potential withdrawal effects. An antidepressant is not a substitute for an antimanic medication. NICE CG185 NIMH
Why isn't lamotrigine used to stop acute mania?
Lamotrigine has not demonstrated sufficient efficacy as a treatment for an acute manic episode, and major guidelines advise against using it for that purpose. It also requires careful titration because of the risk of serious rash. Its possible role in other phases of bipolar disorder does not change the acute-mania evidence. NICE CG185 VA/DoD DailyMed lamotrigine
What if mania returns while taking medication?
A recurrence should prompt timely reassessment of episode severity and immediate safety. A specialist reviews adherence, treatment response, sleep, substance use, medication interactions, and medical contributors. The resulting plan may involve adjusting treatment, changing the agent, or adding an evidence-supported medication under supervision. If psychosis, dangerous behavior, suicidality, or inability to care for oneself develops, urgent in-person services are appropriate. VA/DoD NICE CG185
How can someone know that mania has resolved?
Clinical improvement includes more regular sleep, reduction of abnormal energy and thought acceleration, improved judgment, safer behavior, and recovery of everyday function. A person's subjective feeling of being 'back to normal' is one part of the evaluation, supplemented by clinical observation and, when appropriate, reports from trusted supporters. It is common to continue follow-up after obvious manic symptoms diminish so that residual difficulties and a new depressive episode can be detected. VA/DoD
Related Articles
References
DailyMed (National Library of Medicine). Divalproex sodium: Prescribing information, warnings, and precautions. Official U.S. drug label.
DailyMed (National Library of Medicine). Lamotrigine: Prescribing information and serious skin-rash warnings. Official U.S. drug label.
DailyMed (National Library of Medicine). Lithium: Prescribing information, toxicity, and monitoring. Official U.S. drug label.
Huang, W., He, S., Liu, M., & Xu, J. (2025). Comparative efficacy, safety, and tolerability of pharmacotherapies for acute mania in adults: A systematic review and network meta-analysis of randomized controlled trials. Molecular Psychiatry, 30, 838–847. https://doi.org/10.1038/s41380-024-02705-3.
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. https://doi.org/10.1176/appi.focus.20230009.
National Institute for Health and Care Excellence. (2014; updated). Bipolar disorder: Assessment and management (CG185). NICE clinical guideline.
National Institute for Health and Care Excellence. (2015; updated). Violence and aggression: Short-term management in mental health, health and community settings (NG10). NICE clinical guideline.
National Institute of Mental Health. Bipolar disorder. NIMH public clinical overview.
National Institute of Mental Health. Brain stimulation therapies. NIMH ECT overview.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for the management of bipolar disorder (Version 2.0). Full official guideline (PDF).